Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Clinical and Experimental Vaccine Research, an esteemed journal published by the Korean Vaccine Society, serves as a vital platform for disseminating groundbreaking research in the fields of Immunology, Infectious Diseases, and Public Health. Since its inception in 2012, this open-access journal has been committed to advancing knowledge and fostering collaboration among professionals dedicated to vaccine development and evaluation. With an impactful presence and a Q3 ranking in several categories on the Scopus index, it reflects a robust commitment to quality, evidenced by its placement within the 41st to 59th percentiles across multiple disciplines related to medicine and health. Situated in Seoul, South Korea, at the Department of Pediatrics, Yonsei University Severance Children's Hospital, the journal not only provides a crucial resource for researchers and practitioners but also enhances the global discourse on vaccination strategies and public health interventions. By contributing to the ongoing dialogue in vaccine research, this journal plays an essential role in shaping future health policies and practices.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Vaccine is a premier academic journal published by Elsevier Science Ltd, dedicated to the field of vaccination and immunization research. With an impact factor and H-index that underscore its significance in the scientific community, this journal has consistently ranked in the Q1 category within various fields, including Immunology and Microbiology, Infectious Diseases, and Public Health. Since its inception in 1983, it has served as a vital resource for researchers, healthcare professionals, and students, providing rigorous peer-reviewed articles that explore important breakthroughs and innovations in vaccine development and deployment. Although it does not operate under an Open Access model, the journal maintains high visibility within academic circles, thanks to its strategic collaborations and widely respected editorial board. By bridging the gaps between laboratory discoveries and clinical applications, Vaccine plays a crucial role in advancing global health initiatives and addressing urgent public health challenges.

Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.